Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feverfew is a perennial herb (*Tanacetum parthenium*) from the Asteraceae family, traditionally used for centuries in European and Mediterranean herbal medicine. The main active compound is **parthenolide**, a sesquiterpene lactone concentrated in the leaves and flowers. Feverfew's best-studied and most common use is for the **prevention of migraine headaches**[1][2][3]. Its pharmacological effects derive primarily from anti-inflammatory and anti-platelet mechanisms, notably inhibiting the synthesis of prostaglandins, leukotrienes, and thromboxanes, as well as noncompetitive inhibition of serotonin-mediated vascular smooth muscle spasmogenesis. Other documented uses include management of **fevers, arthritis, menstrual irregularities, stomach aches, toothache, insect bites, and inflammatory skin diseases (e.g., psoriasis)**[1][3][5][6][8]. There is limited and mixed clinical evidence for most uses except migraine prophylaxis; preclinical and mechanistic data suggest wide-ranging anti-inflammatory, analgesic, antispasmodic, and antimicrobial effects, mainly attributable to parthenolide and flavonoid glycosides[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on feverfew.